AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Related Articles
Inside Mayo Clinic’s AI Factory: How Mayo Clinic is looking to use AI to enhance patient care and clinical decision making
AI Data & Analytics Network: One of the most consequential applications of artificial intelligence (AI) and machine learning (ML) is medicine. Though medical AI is still in its infancy, experts predict that within the…February 28, 2021
Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the…December 16, 2022
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosisJune 21, 2023
Philips Launches ECG-AI Marketplace to Enhance Early Cardiac Diagnosis
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystemJuly 17, 2025